Media Bias for Past 90 Days

( is not an official Helium source)

Average Social Media Shares: 0          Average Emotion: 0 Most Recent Articles

Cannabidiol Market Anticipated To Grow At A Lucrative Rate Through 2027 As Consumer Demand Rapidly Increases

economy and finances

PALM BEACH, Fla., March 2, 2021 /PRNewswire/ -- Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products. Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. According to reports from Grand View Research the global cannabidiol; market size is expected to reach USD 13.4 billion by 2028, and is expected to expand at a CAGR of 21.2% from 2021 to 2028. The report said: "Increasing awareness about the health benefits of cannabidiol (CBD), changing consumer opinion, and attitude toward CBD products are some of the key factors driving the demand for these products. Furthermore, increasing demand for cannabidiol from various end-user industries such as food and beverage, personal care and cosmetics, and pharmaceuticals is expected to trigger market growth…" Active Companies active today in the cannabis related markets include: Discover Wellness Solutions Inc. (CSE: WLNS), HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF), Canopy Growth Corporation, (TSX: WEED) (NASDAQ: CGC), Aphria Inc. (TSX: APHA) (NASDAQ: APHA), Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF).     Mar 02, 2021

Revenues Continue to Jump for Legal Cannabis Market Expected to Exceed $73 Billion By 2027


PALM BEACH, Fla., Feb. 16, 2021 /PRNewswire/ -- It seems that every new report concerning future revenues for the legal cannabis market, projects higher numbers that all previous reports. What they DO agree on is that the market has had several robust years of recent growth and shows every sign that the future will continue to outperform projections. A report from Arcview predicted that global legal cannabis sales will hit $42.7 billion by 2024, but it was quickly outpaced by a report from Grand View Research that said that the global legal marijuana market size is expected to reach USD 73.6 billion by 2027, and it is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. The Grand View report said: "On the basis of type, the medical segment held the leading revenue share of 71.0% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson's disease, and Alzheimer's disease among other neurological conditions. Moreover, the increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand. Based on product type, the legal marijuana buds segment accounted for the largest market share in terms of revenue... Buds are primary plant products and are readily available without any processing, which makes them relatively affordable for low-income patients. Moreover, the rapid onset of action of smoking buds compared to other types is anticipated to further fuel the segment growth." Active Companies active today in the cannabis related markets include: Item 9 Labs Corp. (OTCQX: INLB), Tilray Inc. (NASDAQ: TLRY), Aphria Inc. (NASDAQ: APHA) (TSX: APHA), MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN), Curaleaf Holdings, Inc. (OTCQX: CURLF) (CSE: CURA).     Feb 16, 2021

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027


PALM BEACH, Fla., Feb. 10, 2021 /PRNewswire/ -- The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to continue to grow at a high rate. Cancer vaccines are considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways. Certain factors that are driving the Cancer Vaccines market's growth include the increasing number of cancer cases, rising investments and government funding in the development of cancer vaccines, and technological developments in cancer vaccines. A report from Fortune Business Insights said that "The increasing prevalence of cervical cancer among female population is a key factor boosting the global Human Papillomavirus Vaccine market growth. In addition to this, the increasing need to reduce HPV infections will also add impetus to the growth in the coming years. Moreover, the governments in several countries are engaging in imposing stringent policies for supplying vaccines to eradicate the burden of this disease thereby boosting the growth of the market in the coming years." Active biotech companies in the Covid-19 developments this week include KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV), Heat Biologics, Inc. (NASDAQ: HTBX), Tyme Technologies, Inc. (NASDAQ: TYME), Onconova Therapeutics, Inc. (NASDAQ: ONTX).     Feb 10, 2021